A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2274 participants.

Also called NCT03689374

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,274 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03689374
  • EudraCT 2017-003219-20
Main results
  • Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial Diabetes, obesity & metabolism, 2022-09 DOI, PubMed 35546450, PMC9545869 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Bosnia & Herzegovina, Bulgaria, Croatia, Czechia, Estonia, Germany, Greece, Hungary, India, Latvia, Lithuania, North Macedonia, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, South Africa, Spain, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03689374. Randomized; no masking; primary purpose treatment. Start 2018-10-01 (actual); primary completion 2021-02-22 (actual). Results posted on 2022-05-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
Acronym
SUSTAIN 11
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Insulin aspart
Intervention (Drug)
Insulin glargine U100
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03689374
Content hash
2f0c226b54f38fb11d32f4d4499b0feb6f0a14d42df88d72e016960a7c6787c9